PIRS Pieris Pharmaceuticals, Inc.

2.35
+0  (0%)
Previous Close 2.35
Open 2.33
Price To book 4.01
Market Cap 101.19M
Shares 43,058,000
Volume 48,335
Short Ratio 0.85
Av. Daily Volume 253,416

SEC filingsSee all SEC filings

  1. 8-K - Current report 17736219
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17723302
  3. 8-K - Current report 17707984
  4. 8-K - Current report 17705733
  5. 8-K - Current report 17639625

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b multiple ascending dose phase to be completed 2Q 2017. Phase 2a trial to be initiated 2Q 2017 with trial to be completed by the end of 2017.
PRS-080
Anemia of chronic disease

Latest News

  1. Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
  2. Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  3. Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update
  4. Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017
  5. Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT
  6. Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST
  7. Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)
  8. Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST
  9. Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA
  10. Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical
  11. Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST
  12. Pieris Announces Management Transition
  13. Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration
  14. Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
  15. What Hedge Fund Sentiment Says About Pieris Pharmaceuticals Inc (PIRS) And Its Peers
  16. Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer
  17. Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016
  18. Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016
  19. Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration